Original Source(s)
Related Content
FDA Clears Golimumab Biosimilars
New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.
May 18, 2026
-
2 min
Serum Urate Goals Tied to Lower CV Risk
Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients
May 11, 2026
-
4 min
Tofacitinib vs Adalimumab Findings Require Caution in RA
Meta-analysis favored tofacitinib for some rheumatoid arthritis outcomes, but high heterogeneity, dose-dependent effects, and JAK inhibitor safety concerns complicate interpretation.
May 8, 2026
-
4 min
